Epigenomics, AstraZeneca to continue oncology biomarker research

By Elaine Rigoli

Tampa, Fla., May 16 - Epigenomics AG has agreed to continue a collaboration with AstraZeneca Ltd. to identify and analyze potential DNA methylation biomarker candidates for use in AstraZeneca's oncology programs.

Under the agreement, Epigenomics will receive research and development fees and may participate in the development of any potential pharmacodiagnostic products resulting from the collaboration. Further financial details were not disclosed.

"This agreement builds on our good relationship and extends the successful biomarker work we did together with AstraZeneca. The partnership with AstraZeneca provides Epigenomics with an exciting opportunity to support clinical evaluation of existing and novel oncology products, and in the long run to participate in the development of potential pharmacodiagnostic products resulting from the collaboration," Epigenomics senior vice president Christina Dahlstroem said in a news release.

Epigenomics, a molecular diagnostic company with a focus on the development of novel products for cancer, has headquarters in Berlin, Germany.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.